Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Santen Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provide signed written informed consent
Have a diagnosis of POAG or OHT in both eyes, or one eye with POAG and the other with OHT.
Qualifying corrected visual acuity in each eye
Qualifying central corneal thickness in each eye
Qualifying Day 1 IOP measurement at 3 time-points in both eyes
Qualifying Anterior chamber angle
You may not be if
History of ocular surgery specifically intended to lower IOP
Subjects who cannot safely discontinue use of ocular hypotensive medications during the wait/washout period
Advanced glaucoma in either eye
Any corneal abnormality or other condition interfering with or preventing reliable Goldmann applanation tonometry
Any ocular surgery or ocular laser treatment within 180 days prior to Screening and throughout the study in either eye
Females who are pregnant, nursing, or planning a pregnancy
Clareo Health | Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6
